Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Talem and Libera Bio will jointly develop novel antibodies for use with MPN delivery. The program will leverage BioStrand’s LENSai® Full Suite of Integrated Intelligence Technology® with Libera Bio’s Multifunctional Polymeric Nanocapsules (MPN Technology®).
Lead Product(s): Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Talem Therapeutics
Deal Size: $155.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 15, 2023